Finally, since BTN2A1 and BTN3A1 are not only expressed on tumor cells but also on Vg9Vd2 T cells and other T cells, the potential for (self-)elimination of immune cells should be taken into consideration when evaluating the safety profile and the presence of immune populations in peripheral blood (28). This evidence concerns the gene BTN3A1 and neoplasm.